News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FOB Synthesis Lands Antibiotic R&D Pact With Pharma Giant AstraZeneca PLC (AZN)


1/28/2014 7:33:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FOB Synthesis, Inc. Announces Option And License Agreement With FDA On Treatment Of Antibiotic-Resistant Bacterial Infections

KENNESAW, Ga.--(BUSINESS WIRE)--FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections. The treatment will potentially combine compounds from AstraZeneca's preclinical beta lactamase inhibitor (BLI) and FOB Synthesis' preclinical Carbapenem antibiotic programs to help break down bacteria's resistance to carbapenems.

Carbapenem antibiotics have been developed and used widely for bacterial infections. However, the drug resistance bacteria have reduced the value of antibacterial chemotherapy recently. In addition, the carbapenem-resistant (CR) of gram-negative bacteria such as Acinetobacter baumannii, Klebsiella pneumoniae, E.coli and Pseudomonas aeruginosa have accordingly increased all over the world. Investigational carbapenem antibiotics developed by FOB Synthesis, FSI-1671 and FSI-1686, will be examined for the treatment of MDR Gram-negative bacterial infection. Combining a carbapenem with a BLI may allow a novel treatment of the multi-drug resistant bacteria.

Dr. Woo-Baeg Choi, FOB Synthesis' Chief Executive Officer, said: "We are pleased with further development of our carbapenem antibiotics in combination of AstraZeneca's BLI program, and we are confident with AstraZeneca's expertise in the anti-infective field for the successful development of this combination therapy." FOB Synthesis was counseled by Lynn Scott, from Kilpatrick Townsend & Stockton LLP, GA.

Under the terms of the agreement, AstraZeneca will develop investigational combinations of compounds through Phase I during the option phase. AstraZeneca will be solely responsible for the development and commercialization of the candidate combination compound through the option phase, and thereafter if the option is exercised by AstraZeneca. Financial details are not to be disclosed under the agreement at this time.

About FOB Synthesis, Inc.

FOB Synthesis, Inc. is a chemistry-driven drug discovery and custom synthesis company dedicated to discovering new therapeutic agents for the treatment of life-threatening infectious diseases. The company's extensive background in synthetic, organic and medicinal chemistry has played a critical role in its success of identifying a novel class of carbapenem antibiotics.

For more information, please visit www.fobsynthesis.com

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com

Contacts

FOB Synthesis, Inc.:
Hyo Jeong Kim, +1 404 601 1414
or
AstraZeneca:
Wendy Dwyer, +1 781-839-4079
or
Kilpatrick Townsend & Stockton LLP.:
Lynn Scott, +1 404 815 6042

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES